• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2021 年顶级胰腺肿瘤文章,为您的癌症患者提供信息。

Top Pancreatic Tumor Articles from 2021 to Inform Your Cancer Patients.

机构信息

Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.

City of Hope, Duarte, CA, USA.

出版信息

Ann Surg Oncol. 2023 Jun;30(6):3437-3443. doi: 10.1245/s10434-023-13277-x. Epub 2023 Mar 14.

DOI:10.1245/s10434-023-13277-x
PMID:36917337
Abstract

BACKGROUND

More than 10,000 publications about pancreatic cancer were found on PubMed during the past year.

METHODS

To best inform patients with pancreatic cancer, the obvious, frequent questions asked during patient counseling when dealing with resectable pancreatic cancer, borderline resectable pancreatic cancer, and unresectable pancreatic cancer were considered.

RESULTS

The publications highlighted are comprehensive on the current management of neoadjuvant therapy for resectable pancreatic cancer, the addition of radiation to neoadjuvant therapy for borderline resectable pancreatic cancer, the utility of arterial resections in unresectable pancreatic cancer, and the role of minimally invasive approach to pancreatic cancer surgical therapy.

CONCLUSION

These articles are high yield and comprehensive review on key issues facing surgical oncologists who operate on pancreatic cancer.

摘要

背景

在过去一年中,PubMed 上发现了超过 10000 篇关于胰腺癌的文献。

方法

为了最好地为胰腺癌患者提供信息,考虑了当处理可切除胰腺癌、边界可切除胰腺癌和不可切除胰腺癌时,在患者咨询中经常出现的明显问题。

结果

所强调的出版物全面介绍了可切除胰腺癌新辅助治疗的当前管理、在边界可切除胰腺癌的新辅助治疗中加入放疗、在不可切除胰腺癌中动脉切除术的应用以及微创方法在胰腺癌手术治疗中的作用。

结论

这些文章是对进行胰腺癌手术的外科肿瘤学家所面临的关键问题的高产量和全面综述。

相似文献

1
Top Pancreatic Tumor Articles from 2021 to Inform Your Cancer Patients.2021 年顶级胰腺肿瘤文章,为您的癌症患者提供信息。
Ann Surg Oncol. 2023 Jun;30(6):3437-3443. doi: 10.1245/s10434-023-13277-x. Epub 2023 Mar 14.
2
Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.边缘可切除胰腺癌的延长新辅助化疗显示出有前景的术后结果和生存率。
Ann Surg Oncol. 2014 May;21(5):1530-7. doi: 10.1245/s10434-014-3486-z. Epub 2014 Jan 29.
3
Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.新辅助治疗后淋巴细胞单核细胞比值低提示边界可切除胰腺癌患者胰切除术后生存不良。
Surgery. 2019 Jun;165(6):1151-1160. doi: 10.1016/j.surg.2018.12.015. Epub 2019 Feb 11.
4
Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer.新辅助治疗与边界可切除胰腺癌患者生存改善相关。
Ann Surg Oncol. 2020 Apr;27(4):1191-1200. doi: 10.1245/s10434-019-08087-z. Epub 2019 Dec 4.
5
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.可切除边缘性胰腺癌临床路径的结果
Ann Surg Oncol. 2016 Apr;23(4):1371-9. doi: 10.1245/s10434-015-5006-1. Epub 2015 Dec 10.
6
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.局部进展期可切除胰腺导管腺癌的新辅助治疗。
Dig Surg. 2019;36(6):455-461. doi: 10.1159/000493466. Epub 2018 Nov 8.
7
Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.可切除交界性胰腺癌患者接受新辅助治疗和手术的生存情况。
Surgery. 2019 Sep;166(3):277-285. doi: 10.1016/j.surg.2019.05.010. Epub 2019 Jul 2.
8
Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.胰体部交界可切除或局部进展期胰腺癌行联合新辅助化疗的整块整块腹腔动脉切除胰体尾切除术的生存影响。
Pancreatology. 2021 Apr;21(3):564-572. doi: 10.1016/j.pan.2021.01.008. Epub 2021 Jan 27.
9
Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.可切除边缘性胰腺癌及新辅助放化疗的作用
Updates Surg. 2016 Sep;68(3):235-239. doi: 10.1007/s13304-016-0392-x. Epub 2016 Sep 15.
10
Multimodality management of borderline resectable pancreatic adenocarcinoma.可切除边缘性胰腺癌的多模式管理
Chin Clin Oncol. 2017 Jun;6(3):27. doi: 10.21037/cco.2017.06.17.

引用本文的文献

1
Development and validation of a new formula to predict standard pancreas volume in Chinese adults using body surface area.一种利用体表面积预测中国成年人标准胰腺体积的新公式的开发与验证
Gland Surg. 2025 Mar 31;14(3):479-487. doi: 10.21037/gs-2024-550. Epub 2025 Mar 25.

本文引用的文献

1
Framework for Training in Minimally Invasive Pancreatic Surgery: An International Delphi Consensus Study.微创胰腺外科培训框架:一项国际德尔菲共识研究。
J Am Coll Surg. 2022 Sep 1;235(3):383-390. doi: 10.1097/XCS.0000000000000278. Epub 2022 May 20.
2
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.术前 mFOLFIRINOX 对比 mFOLFIRINOX 联合短程放疗治疗边界可切除胰腺腺癌的疗效:A021501 期随机临床试验。
JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319.
3
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
(m)FOLFIRINOX 新辅助放疗治疗边界可切除胰腺腺癌:TAPS 联盟研究。
J Natl Compr Canc Netw. 2022 Jul;20(7):783-791.e1. doi: 10.6004/jnccn.2022.7008.
4
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.可切除和交界可切除胰腺癌的新辅助治疗或 upfront 手术:随机对照试验的荟萃分析。
Eur J Cancer. 2022 Jan;160:140-149. doi: 10.1016/j.ejca.2021.10.023. Epub 2021 Nov 24.
5
Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma.新辅助放射治疗在胰腺腺癌治疗中的价值
J Clin Oncol. 2021 Dec 1;39(34):3773-3777. doi: 10.1200/JCO.21.01220. Epub 2021 Oct 8.
6
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial.腹腔镜与开腹胰十二指肠切除术治疗胰腺或壶腹周围肿瘤:一项多中心、开放标签、随机对照试验。
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):438-447. doi: 10.1016/S2468-1253(21)00054-6. Epub 2021 Apr 27.
7
Outcomes of a Multicenter Training Program in Robotic Pancreatoduodenectomy (LAELAPS-3).多中心机器人胰十二指肠切除术培训项目(LAELAPS-3)的结果。
Ann Surg. 2022 Dec 1;276(6):e886-e895. doi: 10.1097/SLA.0000000000004783. Epub 2021 Feb 1.
8
The Landmark Series: Minimally Invasive Pancreatic Resection.里程碑系列:微创胰腺切除术。
Ann Surg Oncol. 2021 Mar;28(3):1447-1456. doi: 10.1245/s10434-020-09335-3. Epub 2020 Dec 19.
9
Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve.胰腺癌手术中的动脉切除:度过学习曲线后效果显著。
Ann Surg. 2022 Apr 1;275(4):759-768. doi: 10.1097/SLA.0000000000004054.
10
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.SWOG S1505 研究的手术结果:吉西他滨/白蛋白紫杉醇对比改良 FOLFIRINOX 用于可切除胰腺导管腺癌围手术期治疗的随机临床试验。
Ann Surg. 2020 Sep 1;272(3):481-486. doi: 10.1097/SLA.0000000000004155.